Genomma Lab Internacional SAB de CV

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: MX01LA010006
MXN
18.02
-0.75 (-4.0%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Genomma Lab Internacional SAB de CV stock-summary
stock-summary
Genomma Lab Internacional SAB de CV
Pharmaceuticals & Biotechnology
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
Company Coordinates stock-summary
Company Details
Edificio Samara, Antonio Dovali Jaime no. 70 Piso 2, Colonia Santa Fe, MEXICO, D.F. None : 01210
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Rodrigo Alonso Herrera Aspra
Independent Chairman of the Board
Ms. Sabrina Lucila Herrera Aspra
Director
Hr. Burkhard Wittek
Director
Mr. Juan Alonso
Independent Director
Mr. Hector Carrillo Gonzalez
Independent Director
Mr. Scott Emerson
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
4,676 Million
(Quarterly Results - Jun 2025)
Net Profit:
355 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

MXN 18,770 Million (Small Cap)

stock-summary
P/E

9.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.46

stock-summary
Return on Equity

16.00%

stock-summary
Price to Book

1.71